NCT07344090 (FEVER) is a NA clinical trial of Puntofarma® FEVER in Fever, Acute Pain, sponsored by Qwince Innovation S.r.l..

Who is sponsoring NCT07344090?

NCT07344090 is sponsored by Qwince Innovation S.r.l..

What drugs are being tested in NCT07344090?

Interventions in NCT07344090: Puntofarma® FEVER.

What condition does NCT07344090 study?

NCT07344090 studies Fever, Acute Pain.

Is NCT07344090 still recruiting?

NCT07344090 is currently recruiting now. Last updated 15 January 2026.

Last reviewed 2026-01-15 · How we verify

NCT07344090: FEVER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

USING A DECISION-MAKING SYSTEM TO SUPPORT THE MANAGEMENT OF FEVER AND ACUTE PAIN IN CHILDREN

Recruiting now NA Last updated 15 January 2026

What this trial tests

NA trial testing Puntofarma® FEVER in Fever, Acute Pain in 100 participants. Currently enrolling.

Timeline

28 December 2025

Primary endpoint
30 May 2026

30 May 2026

Quick facts

Lead sponsor	Qwince Innovation S.r.l.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	100
Start date	28 December 2025
Primary completion	30 May 2026
Estimated completion	30 May 2026
Sites	1 location across Italy

Drugs / interventions tested

Puntofarma® FEVER

Conditions studied

Fever, Acute Pain — all drugs for Fever, Acute Pain →

Sponsor

Qwince Innovation S.r.l.

Who can join

Adults 3 Months to 5, any sex, with Fever, Acute Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

FEVER is a single-center, prospective, open-label, pre-market, pivotal, single-arm study aimed at demonstrating how the use of an algorithm integrated with a Class I Medical Device (Puntofarma®), which is made available through a downloadable mobile phone app, can, given specific input, improve the appropriateness and adherence to therapy for the management of fever and pain in children between 3 months and 1 day and 5 years of age. 100 patients are expected to be enrolled, equally distributed between febrile patients (50%) and patients with acute pain (50%). Patients admitted to the Regional Pediatric Emergency Department of the Meyer IRCCS Hospital in the presence of a feverish episode and/or acute pain will be enrolled upon discharge. The study will last a total of 8 months (Jan - Aug 2026), with enrollment expected by Jan 2026. Each patient will be involved in the study for a maximum of 7 days from enrollment, during which they will use the mobile app. Participation in the study will conclude by the seventh day of use of the app, with the completion of a satisfaction questionnaire.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07344090 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qwince Innovation S.r.l.
Last refreshed: 15 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07344090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing